All patients underwent the QuickVue Influenza A + B test (Quidel, San Diego, CA, USA). Additionally, peripheral blood from patients and asymptomatic healthy contacts (AHC) was collected; these interventions adhered to the guidelines and recommendations of the Centers for Disease Control and Prevention of the United States (CDC) and the World Health Organization (WHO). Subsequently, the RespiFinder assay was administered, and the presence of influenza A (H1N1) virus was confirmed.
Quickvue influenza a b test
Manufactured by Quidel
Sourced in United States
The QuickVue Influenza A + B test is a rapid, qualitative lateral flow immunoassay for the detection of influenza type A and type B antigens in direct nasal or nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection. The test is intended to aid in the rapid diagnosis of influenza A and B viral infections.
Automatically generated - may contain errors
Lab products found in correlation
6 protocols using quickvue influenza a b test
1
Influenza A (H1N1) Diagnostic Protocol
2
Influenza A/H1N1 Rapid Screening Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients underwent the QuickVue Influenza A + B test (Quidel, San Diego, CA, USA). Additionally, peripheral blood from patients and asymptomatic healthy contacts (HC) was collected; these interventions adhered to the guidelines and recommendations of the Centers for Disease Control and Prevention of the United States (CDC) and the World Health Organization (WHO). Subsequently, the RespiFinder assay was done, and the presence of the influenza A/H1N1 virus was confirmed.
3
Rapid Influenza A+B Detection
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NP swab samples were applied to the QuickVue Influenza A + B Test (Quidel, San Diego, CA) using the manufacturer’s instructions [15 ]. Colorimetric tests were read by eye to determine positive or negative results as per protocol in the test kit insert. All samples reported in this analysis properly displayed positive procedural control lines, indicating successful execution of the test kit protocol [15 ].
4
Influenza Rapid Test and Symptoms
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Adults and children aged ≥ 1 year were included year-round (n = 2980; excluding 21 patients (1%) with mixed influenza A and B virus infections) in the study if they were influenza-positive by rapid test (QuickVue Influenza A + B Test; Quidel Corp) at presentation and/or had predefined clinical signs and symptoms of influenza for ≤ 48 h for hospitalized patients (no time limit for hospitalized children). The vast majority (> 97%) had uncomplicated influenza.
5
Rapid Influenza A+B Detection
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Nasopharyngeal swabs were taken from the subjects and eluted in 800 μL saline by vigorously rotating the swab in the diluent. Each sample was analyzed using rapid QuickVue Influenza A + B test (Quidel, CA, USA) following the recommendations for collection and testing from US Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO). Positive cases for influenza A H1N1 confirmed by QuickVue were further validated using an RT-PCR-based RespiFinder 22 test (Maastricht, Netherlands) [21 (link)].
6
Retrospective analysis of influenza infections
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We performed a retrospective analysis of all patients with laboratory-confirmed infection with influenza A or B viruses between December 2017 and May 2018 in the Rostock University Medical Center, a 1100-bed tertiary referral hospital. All hospitalized patients as well as patients admitted to the emergency room or treated in outpatient clinics were included. The ethical committee of the Rostock University Medical Center approved the study (A 2018-0039). Informed consent was not required due to the observational nature of the study. Diagnostic procedures of respiratory specimens were performed using antigen immunoassays (QuickVue Influenza A + B Test, Quidel Corporation, San Diego, USA) and molecular analysis (GeneXpert® Flu/RSV XC-System, Cepheid, Sunnyvale, USA), according to the manufacturers’ protocols. If the antigen test was negative, a polymerase chain reaction (PCR) was performed. All patients with positive influenza antigen or positive influenza PCR were included. In case of repeated positive influenza tests, only the first test was included.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!